{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Disease response - the proportion of patients with high risk smoldering multiple myeloma who do not progress to symptomatic myeloma as defined by the IMWG.","groups":[{"description":"Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis\n\nIbrutinib: Ibrutinib is a type of drug called a \"kinase inhibitor.\" Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing.","id":"OG000","title":"Ibrutinib"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"up to 1 year","title":"Number of Patients Without Symptomatic Myeloma","type":"PRIMARY","unitOfMeasure":"Participants"}